Clinical Study Of Cardiovascular Adverse Effects Caused By Bevacizumab In Patients With Non-Small Cell Lung Cancer

Purpose: In this study,we analyzed the changes in cardiac-related indicators in patients with lung cancer treated with bevacizumab(BVZ)to investigate the cardiovascular adverse effects caused by BVZ in patients with non-small cell lung cancer(NSCLC)and its associated risk factors.Methods: Fifty-one NSCLC patients with no previous history of serious cardiovascular disease and diagnosed by pathological histology or cytology as having intermediate to advanced stage lost to surgery who attended the Cancer Hospital of Xinjiang Medical University from January 2018 to December 2021 were selected and divided into two groups.About the availability of bevacizumab and bevacizumab(study group,n=26)and chemotherapy alone(control group,n=25).Fifty-one cases meeting the requirements of the experiment were recruited,and the patients’ general information(e.g.gender,age,clinical stage,history of smoking,history of diabetes)and ancillary test results(e.g.blood pressure,ECG,cardiac enzyme profile,troponin,B-type natriuretic peptide(BNP),platelets,D-dimer,cardiac ultrasound,vascular ultrasound of the extremities)were used for the study.(ultrasound)were processed and statistically analyzed using SPSS26.0 software,and the difference was considered statistically significant at P<0.05.Results:(1)When comparing the study group with the control group,There was no significant difference in basic clinical data among patients of different genders,ages and clinical stages,smoking history and diabetes history(P>0.05).2)When comparing the study group with the control group,there was a statistically significant difference in the incidence of hypertension,ECG abnormalities and D-dimer elevation(P < 0.05).3)Whether the general clinical information was correlated with hypertension,ECG abnormalities(3)Whether general clinical information was correlated with hypertension,ECG abnormalities,and the incidence of D-dimer elevation.The results of multivariate Logistic regression showed that smoking was significantly correlated with hypertension and the increase of D-dimer.Conclusion: Bevacizumab(BVZ)can cause adverse effects such as cardiac damage,which can lead to elevated blood pressure,elevated D-dimer levels,and abnormal electrocardiograms,and a history of smoking is a common risk factor for elevated blood pressure and elevated D-dimer levels,which can be considered as indicators of cardiovascular adverse effects of BVZ for early detection of cardiac damage.